Harrell Investment Partners LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Harrell Investment Partners LLC has purchased 2,010 shares of Regeneron Pharmaceuticals, Inc., valued at approximately $1,055,000, indicating increasing institutional interest in the biopharmaceutical company.
• Regeneron reported a net margin of 31.37% and earnings per share (EPS) of $12.89 for the last quarter, surpassing estimates, with revenue of $3.68 billion for the period.
• Multiple analysts have raised their price targets for Regeneron shares, with BMO Capital Markets setting a target of $640 and Morgan Stanley adjusting their target to $761, further reflecting strong market sentiment.

Harrell Investment Partners LLC purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 2,010 shares of the biopharmaceutical company's stock, valued at approximately $1,055,000.

A number of other institutional investors also recently bought and sold shares of REGN. Adirondack Trust Co. grew its stake in shares of Regeneron Pharmaceuticals by 4.2% during the 1st quarter. Adirondack Trust Co. now owns 451 shares of the biopharmaceutical company's stock worth $286,000 after purchasing an additional 18 shares during the period. Kingswood Wealth Advisors LLC grew its stake in shares of Regeneron Pharmaceuticals by 1.8% during the 1st quarter. Kingswood Wealth Advisors LLC now owns 1,084 shares of the biopharmaceutical company's stock worth $681,000 after purchasing an additional 19 shares during the period. Creative Financial Designs Inc. ADV grew its stake in shares of Regeneron Pharmaceuticals by 9.5% during the 1st quarter. Creative Financial Designs Inc. ADV now owns 220 shares of the biopharmaceutical company's stock worth $139,000 after purchasing an additional 19 shares during the period. Private Trust Co. NA grew its stake in shares of Regeneron Pharmaceuticals by 13.1% during the 1st quarter. Private Trust Co. NA now owns 164 shares of the biopharmaceutical company's stock worth $104,000 after purchasing an additional 19 shares during the period. Finally, Proficio Capital Partners LLC grew its stake in shares of Regeneron Pharmaceuticals by 6.2% during the 1st quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company's stock worth $207,000 after purchasing an additional 19 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $576.98 on Thursday. The company's fifty day moving average price is $569.25 and its 200 day moving average price is $573.47. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,070.00. The stock has a market capitalization of $61.15 billion, a P/E ratio of 14.54, a P/E/G ratio of 1.81 and a beta of 0.35. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company had revenue of $3.68 billion for the quarter, compared to analysts' expectations of $3.30 billion. During the same quarter in the previous year, the company posted $11.56 EPS. The firm's quarterly revenue was up 3.6% on a year-over-year basis. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Monday, August 18th. Regeneron Pharmaceuticals's payout ratio is 8.87%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. BMO Capital Markets raised their price objective on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an "outperform" rating in a research note on Monday, August 4th. Morgan Stanley reaffirmed an "overweight" rating and set a $761.00 price objective (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Redburn Atlantic raised shares of Regeneron Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, August 14th. Canaccord Genuity Group reissued a "buy" rating and issued a $850.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, July 23rd. Finally, Guggenheim lifted their price target on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Three research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $817.67.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.